Published Paper Details:

Bioavailability refers to the fraction of administered drug that reaches the systemic circulation in an unchanged form and is available to exert its therapeutic effects. It is the rate and extent to which a drug is absorbed from its dosage form and becomes available at the site of action. Bioavailability and bioactivity both the concepts are related to the effectiveness of drugs. The term pharmacological response is directly related to our body's blood plasma levels. Thus, bioavailability is defined as the rate and extent (amount) of absorption of an unchanged drug from its dosage form. An ideal drug must have to live within the body and must not reform the properties of biomolecules apart from target molecules. Nano drug delivery systems, also known as nanocarriers or nanomedicines, refer to a class of pharmaceutical formulations that utilize nanotechnology to deliver drugs or therapeutic agents to specific target sites within the body. Nanotechnology offers precise control over the design and fabrication of drug delivery systems. By encapsulating drugs within nanoparticles or nanocarriers, their stability, solubility, and targeted delivery can be improved. Nanoparticles can protect drugs from degradation, enhance their absorption, and enable controlled release, thus improving bioavailability. Nanoparticles can be engineered to specifically target diseased cells or tissues while sparing healthy ones. Functionalized nanoparticles can be designed to attach to specific molecules or receptors found on cancer cells, for instance. This targeted approach reduces systemic side effects and enhances the bioactivity of therapeutic agents.